1/19
Vocabulary practice flashcards covering tumour marker definitions, historical milestones, clinical roles, classifications, specific diagnostic markers, and cut-off values based on the lecture by Dr. Eyam DSE.
Tumour markers
A group of proteins, hormones, enzymes, receptors, and other cellular products that are overexpressed by malignant cells or produced by the body in response to cancer growth, detectable in blood, urine, or tissue samples.
Bence-Jones protein
The first recognized tumour marker in historical medical practice.
Lead time
A characteristic of an ideal tumour marker denoting the interval of earlier detection or advance warning it provides compared to the standard clinical presentation.
Screening
The process of looking for cancer in individuals who have no symptoms of the disease.
Early detection
Finding cancer at an early stage when it is less likely to have spread and is easier to treat.
Her2/neu
A tumour marker that guides treatment by indicating therapy responsiveness; breast cancer patients positive for this marker are more likely to respond to Herceptin.
Ectopic hormone production
The production and secretion of hormones by tissues that do not normally synthesize them, occurring as a result of malignancy (e.g., ACTH or calcitonin).
Oncofetal antigens
The largest class of tumour markers, consisting of proteins coded by genes active during foetal development that function at low levels after birth but are reactivated by malignant tumours to produce high amounts of protein.
Alpha-fetoprotein (AFP)
A foetal glycoprotein used prenatally to detect spina bifida and CSF leakage; in non-pregnant adults, levels above 300ng/L suggest malignancy or liver disease, levels above 1000ng/L almost always indicate cancer, and it is elevated in nearly all yolk sac tumours and 80% of malignant liver tumours.
CA-125
A carbohydrate antigen marker used for the diagnosis, monitoring, and mass-correlation of ovarian cancer (elevated in approximately 75% of cases overall, 50% of Stage I, and 90% of Stage II or higher), as well as 20% of pancreatic cancers.
Carcinoembryonic antigen (CEA)
A cell membrane glycoprotein that reaches very high levels in colorectal cancer, is elevated in over 50% of many carcinomas, and is monitored in plasma to assess whether second-look surgery should be performed.
Prostate specific antigen (PSA)
A small glycoprotein with protease activity specific for prostate tissue that is elevated in benign prostatic hypertrophy, prostatitis, and in more than 60% of Stage A and 70% of Stage B prostate cancers.
Free PSA
The portion of prostate specific antigen circulating unbound to protein in plasma; a low fraction in patients with a borderline total PSA of 4–10ng/L indicates a higher probability of prostate malignancy.
Oestrogen receptor (ER)
A nuclear receptor protein in breast and uterine tissues used to evaluate whether a breast cancer patient will respond to tamoxifen therapy, where levels greater than 10fmol/mg protein are considered positive.
Progesterone receptor (PR)
A marker consisting of two nuclear proteins in breast and uterine tissues; when co-positive with ER, patients have a greater than 60% chance of tumour shrinkage with endocrine therapy, compared to less than 5% if both are negative.
Human chorionic gonadotropin (hCG)
A glycoprotein produced by trophoblast cells and the developing placenta that serves as a tumour marker for choriocarcinoma, trophoblastic tumours, and approximately 60% of testicular cancers.
Nuclear matrix protein (NMP22)
A structural nuclear protein released into the urine when bladder carcinoma cells die; it is positive in approximately 70% of bladder carcinomas.
Bladder tumour-associated analytes (BTA)
A urinary marker comprised of type IV collagen, fibronectin, laminin, and proteoglycan, elevated in about 30% of low-grade and over 60% of high-grade bladder tumours.
Oncogenes (Tumour Markers)
Genes active during foetal development that trigger tumour growth upon activation in mature cells; their products include BRAC-1, myc, p53, RB gene, and Ph 1.
Second-look surgery
A repeat surgical intervention whose necessity is evaluated in patients by tracking serial plasma concentrations of carcinoembryonic antigen (CEA).